Q-omics provides the consensus-scored OR2AT4 profile across patient tissues and cancer cell-line models. OR2AT4 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, OR2AT4 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, OR2AT4 RNA expression shows 6,301 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, KIRC, and STAD as cancer lineages where OR2AT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2AT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2AT4 survival associations across molecular data types. OR2AT4 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2AT4 RNA expression–survival associations across cancer types. High OR2AT4 expression shows unfavorable associations in LUAD, LIHC, LUSC, KIRC, UCS and KICH. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for OR2AT4 RNA expression.
This table summarizes OR2AT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR2AT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2AT4 shows higher tumor expression in KIRC, KIRP, LUAD and LIHC. The KIRC box plot shows higher OR2AT4 RNA expression in tumor versus normal tissue (log2 FC = +0.108, t-test p < 0.001).
This table shows molecular features associated with OR2AT4 in patient tissues and cancer cell lines. In patient samples, OR2AT4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR2AT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
